Head-To-Head Comparison: Longevity Health (XAGE) and Its Rivals

Valuation & Earnings

This table compares Longevity Health and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Longevity Health	$1.05 million	-$10.37 million	-0.06
Longevity Health Competitors	$61.19 million	-$27.52 million	1.49

Longevity Health’s rivals have higher revenue, but lower earnings than Longevity Health. Longevity Health is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Longevity Health has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, Longevity Health’s rivals have a beta of 1.80, suggesting that their average stock price is 80% more volatile than the S&P 500.

Profitability

This table compares Longevity Health and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Longevity Health Competitors	-569.68%	-123.14%	-53.62%

Institutional and Insider Ownership

24.2% of Longevity Health shares are held by institutional investors. Comparatively, 19.3% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by institutional investors. 29.0% of Longevity Health shares are held by insiders. Comparatively, 19.9% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Longevity Health rivals beat Longevity Health on 5 of the 9 factors compared.

Longevity Health Company Profile

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.